Search JTA's historical archive dating back to 1923

News Brief

The Food and Drug Administration has approved a treatment for bone-marrow cancer based on research conducted in Israel. The velcade injection, developed by Millennium Pharmaceuticals of Cambridge, Mass., following 30 years of research by professor Avraham Hershko of Israel’s Technion, is the “first in a new class of anti-cancer agents known as proteasome inhibitors.”

October 2, 2003
See Original Daily Bulletin From This Date
Advertisement

The Food and Drug Administration has approved a treatment for bone-marrow cancer based on research conducted in Israel. The velcade injection, developed by Millennium Pharmaceuticals of Cambridge, Mass., following 30 years of research by professor Avraham Hershko of Israel’s Technion, is the “first in a new class of anti-cancer agents known as proteasome inhibitors.”

Recommended from JTA

Advertisement